Mesoblast limited (NASDAQ:MESO) Expected to Post Quarterly Sales of $16.41 Million

Wall Street brokerages expect Mesoblast limited (NASDAQ:MESO) to announce sales of $16.41 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Mesoblast’s earnings, with the highest sales estimate coming in at $16.48 million and the lowest estimate coming in at $16.35 million. Mesoblast reported sales of $11.64 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 41%. The firm is expected to report its next earnings report on Thursday, November 21st.

According to Zacks, analysts expect that Mesoblast will report full-year sales of $37.42 million for the current fiscal year, with estimates ranging from $9.80 million to $61.18 million. For the next fiscal year, analysts forecast that the firm will report sales of $98.83 million, with estimates ranging from $47.93 million to $149.73 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Mesoblast.

Mesoblast (NASDAQ:MESO) last announced its earnings results on Thursday, August 29th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. Mesoblast had a negative net margin of 536.97% and a negative return on equity of 17.66%. The firm had revenue of $1.97 million for the quarter, compared to the consensus estimate of $1.31 million.

A number of analysts have recently issued reports on MESO shares. Chardan Capital set a $6.00 price objective on shares of Mesoblast and gave the company a “hold” rating in a report on Friday, August 30th. ValuEngine raised shares of Mesoblast from a “buy” rating to a “strong-buy” rating in a research note on Monday, September 16th. Cantor Fitzgerald set a $23.00 target price on shares of Mesoblast and gave the company a “buy” rating in a research note on Tuesday, September 10th. Maxim Group reissued a “buy” rating and issued a $16.00 target price on shares of Mesoblast in a research note on Thursday, September 12th. Finally, HC Wainwright set a $7.00 target price on shares of Mesoblast and gave the company a “buy” rating in a research note on Friday, August 30th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $11.63.

An institutional investor recently raised its position in Mesoblast stock. Morgan Stanley boosted its stake in shares of Mesoblast limited (NASDAQ:MESO) by 284.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 147,702 shares of the company’s stock after purchasing an additional 109,295 shares during the quarter. Morgan Stanley owned about 0.16% of Mesoblast worth $784,000 at the end of the most recent reporting period. 2.60% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ MESO remained flat at $$6.70 during midday trading on Friday. 22,576 shares of the stock were exchanged, compared to its average volume of 49,457. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.41 and a quick ratio of 1.41. Mesoblast has a 12 month low of $3.35 and a 12 month high of $8.78. The company has a market cap of $668.19 million, a PE ratio of -7.36 and a beta of 1.77. The stock has a fifty day simple moving average of $5.53 and a 200 day simple moving average of $5.26.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

See Also: Bond

Get a free copy of the Zacks research report on Mesoblast (MESO)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with's FREE daily email newsletter.